Circulating CO3-610, a degradation product of collagen III, closely reflects liver collagen and portal pressure in rats with fibrosis

Fibrogenesis and Tissue Repair

Volumn 4, Issue 1, 2011, Pages

  Segovia Silvestre, Toni ^a   Reichenbach, Vedrana ^b   Fernández Varo, Guillermo ^b   Vassiliadis, Efstathios ^a   Barascuk, Natasha ^a   Morales Ruiz, Manuel ^b   Karsdal, Morten A ^a   Jiménez, Wladimiro ^b,c  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CO3 610; COLLAGEN DERIVATIVE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GELATINASE A; GELATINASE B; HYALURONIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; GENE EXPRESSION; LIPID BLOOD LEVEL; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; RAT;

EID: 80052806957     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-4-19     Document Type: Article

References (35)

1. Castera L, Pinzani M. Biopsy and non-invasive methods fot the diagnosis of liver fibrosis: does it take two to tango?. Gut 2010, 59:861-866. 10.1136/gut.2010.214650, 20581229.
2. Castera L, Pinzani M. Non invasive assessment of liver fibrosis: are we ready?. Lancet 2010, 375:1419-1420. 10.1016/S0140-6736(09)62195-4, 20417845.
3. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroeneterology 2008, 134:1655-1669.
4. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001, 344:495-500. 10.1056/NEJM200102153440706, 11172192.
5. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004, 99:1160-1174. 10.1111/j.1572-0241.2004.30110.x, 15180741.
6. Gressner AM, Gao CF, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World J Gastroenterol 2009, 15:2433-2440. 10.3748/wjg.15.2433, 2686898, 19468990.
7. Talwalkar JA. Antifibrotic therapies--emerging biomarkers as treatment end points. Nat Rev Gastroenterol Hepatol 2010, 7:59-61. 10.1038/nrgastro.2009.197, 20051972.
8. Carrion JA, Fernandez-Varo G, Bruguera M, Garcia-Pagan JC, Garcia-Valdecasas JC, Perez-Del-Pulgar S, et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 2010, 138:147-158. 10.1053/j.gastro.2009.09.047, 19786026.
9. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996, 42:558-563.
10. Guechot J, Loria A, Serfaty L, Giral P, Guiboudeau J, Poupon R. Serum Hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol 1995, 22:22-26. 10.1016/0168-8278(95)80255-X, 7751583.
11. Shimizu I, Omoya T, Takaoka T, Wada S, Wada H, Taoka M, et al. Serum amino-terminal propeptide of type III procollagen and 7S domain of type IV collagen correlate with hepatic iron concentration in patients with chronic hepatitis C following alpha-interferon therapy. J Gastroenterol Hepatol 2001, 16:196-201. 10.1046/j.1440-1746.2001.02402.x, 11207901.
12. Veidal SS, Bay-Jensen AC, Tougas G, Karsdal MA, Vainer B. Serum markers of liver fibrosis: combining the BIPED classification and the neo-epitope approach in the development of new biomarkers. Dis Markers 2010, 28:15-28.
13. Barascuk N, Veidal SS, Larsen L, Larsen DV, Larsen MR, Wang J, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem 2010, 43:899-904. 10.1016/j.clinbiochem.2010.03.012, 20380828.
14. Veidal SS, Vassiliadis E, Barascuk N, Zhang C, Segovia-Silvestre T, Klickstein L, et al. Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis. Liver Int 2010, 30:1293-1304. 10.1111/j.1478-3231.2010.02309.x, 20666994.
15. Jensen CH, Hansen M, Brandt J, Rasmussen HB, Jensen PB, Teisner B. Quantification of the N-terminal propeptide of human procollagen type I (PINP): comparison of ELISA and RIA with respect to different molecular forms. Clin Chim Acta 1998, 269:31-41. 10.1016/S0009-8981(97)00182-4, 9498102.
16. Bigg HF, Rowan AD, Barker MD, Cawston TE. Activity of matrix metalloproteinase- against native collagen types I and III. FEBS J 2007, 274:1246-1255. 10.1111/j.1742-4658.2007.05669.x, 17298441.
17. Zhen EY, Brittain IJ, Laska DA, Mitchell PG, Sumer EU, Karsdal MA, et al. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 2008, 58:2420-2431. 10.1002/art.23654, 18668564.
18. Vassiliadis E, Vang Larsen D, Elgaard Clausen R, Veidal SS, Barascuk N, Larsen L, et al. Measurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type III, in a rat model of reversible carbon-tetrachloride-induced fibrosis. Biomarkers Insight 2011, 6:49-58.
19. Blasco A, Forns X, Carrion JA, Garcia-Pagan JC, Gilabert R, Rimola A, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006, 43:492-499. 10.1002/hep.21090, 16496308.
20. Yachida S, Wakabayashi H, Okano K, Suzuki Y. Prediction of posthepatectomy hepatic functional reserve by serum hyaluronate. Br J Surg 2009, 96:501-508. 10.1002/bjs.6560, 19358182.
21. Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, et al. Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology 2009, 136:160-167. 10.1053/j.gastro.2008.09.013, 18992746.
22. Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008, 47:789-798. 10.1002/hep.22099, 18175357.
23. Rojkind M, Giambrone MA, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology 1979, 76:710-719.
24. Nakatsukasa H, Nagy P, Evarts RP, Hsia CC, Marsden E, Thorgeirsson SS. Cellular distribution of transforming growth factor-beta 1 and procollagen types I, III, and IV transcripts in carbon tetrachloride-induced rat liver fibrosis. J Clin Invest 1990, 85:1833-1843. 10.1172/JCI114643, 296648, 1693377.
25. Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med 1991, 324:933-940. 10.1056/NEJM199104043241401, 1900574.
26. Annoni G, Weiner FR, Zern MA. Increased transforming growth factor-beta 1 gene expression in human liver disease. J Hepatol 1992, 14:259-264. 10.1016/0168-8278(92)90168-O, 1380023.
27. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis -- a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007, 46:955-975. 10.1016/j.jhep.2007.02.003, 17383048.
28. Takahara T, Furui K, Funaki J, Nakayama Y, Itoh H, Miyabayashi C, et al. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 1995, 21:787-795. 10.1002/hep.1840210328, 7875677.
29. Milani S, Herbst H, Schuppan D, Grappone C, Pellegrini G, Pinzani M, et al. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 1994, 144:528-537. 1887080, 8129038.
30. Kossakowska AE, Edwards DR, Lee SS, Urbanski LS, Stabbler AL, Zhang CL, et al. Altered balance between matrix metalloproteinases and their inhibitors in experimental biliary fibrosis. Am J Pathol 1998, 153:1895-1902. 10.1016/S0002-9440(10)65703-3, 1866318, 9846979.
31. Knittel T, Mehde M, Grundmann A, Saile B, Scharf JG, Ramadori G. Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat. Histochem. Cell Biol 2000, 113:443-453.
32. Gieling RG, Wallace K, Han YP. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 2009, 296:G1324-1331. 10.1152/ajpgi.90564.2008, 2697947, 19342509.
33. Vempati P, Karagiannis ED, Popel AS. A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem 2007, 282:37585-37596. 10.1074/jbc.M611500200, 17848556.
34. Clària J, Jiménez W. Renal dysfunction and ascites in carbon tetrachloride-induced cirrhosis in rats. The Liver and the Kidney 1999, 379-396. Arroyo V, Schrier RW, Rodés J, Ginès P. Boston: Blackwell Science.
35. Muñoz-Luque J, Ros J, Fernández-Varo G, Tugues S, Morales-Ruiz M, Alvarez CE, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008, 324:475-483. 2887659, 18029545.